Short Interest in Nanobiotix S.A. (NASDAQ:NBTX) Increases By 37.6%

Posted by Tech Dows on Mar 18th, 2025

Nanobiotix S.A. (NASDAQ:NBTX – Get Free Report) was the target of a large increase in short interest in February. As of February 28th, there was short interest totalling 29,300 shares, an increase of 37.6% from the February 13th total of 21,300 shares. Based on an average daily volume of 32,500 shares, the short-interest ratio is presently 0.9 days. Approximately 0.1% of the company’s stock are sold short.

Hedge Funds Weigh In On Nanobiotix

Institutional investors and hedge funds have recently bought and sold shares of the stock. Geode Capital Management LLC purchased a new position in Nanobiotix during the fourth quarter valued at $29,000. Millennium Management LLC purchased a new position in Nanobiotix during the fourth quarter valued at $39,000. Jane Street Group LLC purchased a new position in Nanobiotix during the fourth quarter valued at $73,000. Finally, OLD Mission Capital LLC purchased a new position in Nanobiotix during the fourth quarter valued at $139,000. 38.81% of the stock is currently owned by hedge funds and other institutional investors.

Nanobiotix Stock Performance

Shares of NBTX stock traded up $0.09 on Monday, reaching $3.33. The stock had a trading volume of 9,265 shares, compared to its average volume of 21,943. Nanobiotix has a 1 year low of $2.76 and a 1 year high of $7.51. The company has a 50 day simple moving average of $3.44 and a 200 day simple moving average of $3.94.

Analyst Ratings Changes

Separately, UBS Group upgraded Nanobiotix to a “hold” rating in a research note on Monday, February 17th.

Check Out Our Latest Report on NBTX

Nanobiotix Company Profile

(Get Free Report)

Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.